Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Proqr Therapeutics Ii B V has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution matter is being handled by a distinct examiner and is located within a distinct art unit. The company's current activity is focused on this single pending action, which represents the entirety of its active examination profile. In the biotechnology field, having a single pending office action suggests a targeted approach to patenting, where the company is currently navigating the specific requirements of a single examiner and art unit.
CHONG, KIMBERLY is the busiest examiner for this portfolio, with 1 pending office action currently under review. This examiner is responsible for the only pending action the company has, meaning the prosecution is concentrated under this individual. The involvement of a distinct art unit further highlights the specialized nature of the pending matter. Because there is only a single distinct examiner involved, the company's current patent strategy is dependent on the specific feedback of this 1 official within the USPTO.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHONG, KIMBERLY | 1 | 72.3% | +13.1% |
| ALLEN, SARAH ELIZABETH | 1 | 56.7% | +33.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18006134 | ANTISENSE OLIGONUCLEOTIDES FOR RNA EDITING | ALLEN, SARAH ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18477366 | NUCLEIC ACID MOLECULES FOR PSEUDOURIDYLATION | CHONG, KIMBERLY | — |
| 18006134 | ANTISENSE OLIGONUCLEOTIDES FOR RNA EDITING | ALLEN, SARAH ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18477366 | NUCLEIC ACID MOLECULES FOR PSEUDOURIDYLATION | CHONG, KIMBERLY | 1636 | §112DP | Non-Final OA | — | Pending | Sep 28, 2023 |
| 18006134 | ANTISENSE OLIGONUCLEOTIDES FOR RNA EDITING | ALLEN, SARAH ELIZABETH | 1637 | §103§112 | Non-Final OA | — | Pending | Jan 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialProqr Therapeutics Ii B V has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Kimberly Chong has the most, with 1 of Proqr Therapeutics Ii B V's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
